Brief: Celcuity Announces FDA Approval Of Revtorpyk™ (Gedatolisib) For The Treatment Of Hr+/Her2-, Pik3ca Wild-Type Locally Advanced Or Metastatic Breast Cancer
US FDA approves Celcuity's breast cancer drug (updated)
Celcuity rises after FDA approval for breast cancer drug
Brief: FDA Approves Celcuity's Gedatolisib for Advanced Breast Cancer
US FDA approves Celcuity's breast cancer drug
U.S. STOCKS ON THE MOVE -Honeywell, Broadcom, Carlyle
U.S. STOCKS ON THE MOVE-UnitedHealth, Pinterest, Celcuity
Celcuity rises after boosted $500 mln convertible bond offering
Brief: Celcuity Inc. Prices Upsized $500 Million 0.25% Convertible Senior Notes Due 2032
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway
Celcuity drops further after announcing $400 mln convertible offering
Brief: Celcuity Inc. Announces Public Offering Of Convertible Senior Notes Due 2032
Brief: Celcuity - Offering $400 Million Convertible Senior Notes Due 2032 - SEC Filing
Celcuity plunges after experimental breast cancer treatment data disappoints
Brief: Celcuity - Announces Phase 3 VIKTORIA-1 Trial Results For PIK3CA MT Cohort - SEC Filing
Biotech firm Celcuity reports smaller-than-expected Q1 loss
Brief: Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
NASDAQ RESUMED AT 05:20 PM